FLAG with Bortezomib Salvage Therapy in Relapsed/Refractory Childhood Leukemia—A Reliable Bridge to Transplantation with Limited Toxicity
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
FLAG with Bortezomib Salvage Therapy in Relapsed/Refractory Childhood Leukemia—A Reliable Bridge to Transplantation with Limited Toxicity ; day:11 ; month:04 ; year:2024
South Asian journal of cancer ; (11.04.2024)
- Contributor
-
Cherulil, Sreedhar Jayakrishnan
Melarcode Ramanan, Kesavan
Gangadharan, KV
Sreelesh, KP
Chandrashekaran, Arun
Vaniyath, Sudeep
KV, Karthika
- DOI
-
10.1055/s-0044-1785695
- URN
-
urn:nbn:de:101:1-2406061008089.766008792959
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cherulil, Sreedhar Jayakrishnan
- Melarcode Ramanan, Kesavan
- Gangadharan, KV
- Sreelesh, KP
- Chandrashekaran, Arun
- Vaniyath, Sudeep
- KV, Karthika
Other Objects (12)
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: extended follow-up subgroup analysis of the BOSTON trial
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: extended follow-up subgroup analysis of the BOSTON trial
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: extended follow-up subgroup analysis of the BOSTON trial
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia